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427Pharmacodynamic Effects of Cangrelor on
Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated PatientsObjectives The purpose of this study was to assess the in vitro P2Y12 receptor inhibitory effects of cangrelor on platelets from
patients on maintenance prasugrel therapy treated with 2 reloading dose regimens.
Background Despite its more potent and rapid antiplatelet effects compared with clopidogrel, recent studies have shown
variability in prasugrel-mediated P2Y12 receptor inhibition, particularly in high-risk settings. Cangrelor is a potent intravenous P2Y12
receptor inhibitor.
Methods A total of 60 patients with coronary artery disease on maintenance prasugrel (10 mg/day) therapy were randomized to a
30- or 60-mg reload of prasugrel. The platelet reactivity index (PRI), as assessed by whole-blood vasodilator-stimulated
phosphoprotein, was measured with and without in vitro incubation of cangrelor (500 nM) at baseline, and at 1 and 4 h after reload.
Results In the absence of cangrelor, prasugrel reloading reduced PRI (p < 0.001 for both doses), although a 60-mg reload had
greater platelet inhibition compared with a 30-mg reload at 4 h (p ¼ 0.001). Cangrelor was associated with a reduction in PRI values
during the overall study time course in patients reloaded with 30 mg (p ¼ 0.001) and 60 mg (p < 0.001) of prasugrel. In patients
reloaded with 30 mg prasugrel, cangrelor decreased PRI at each time point (baseline, p < 0.001; 1 h, p ¼ 0.013; 4 h, p ¼ 0.001). In
patients reloaded with 60 mg prasugrel, cangrelor decreased PRI at baseline (p < 0.001) and 1 h (p ¼ 0.002); levels of platelet
reactivity comparable to those achieved with cangrelor were observed only at 4 h (p ¼ 0.325). The intergroup comparisons with
cangrelor were not signiﬁcant at any time point.
Conclusions In patients on maintenance prasugrel therapy exposed to a reloading dose (30 or 60 mg) of prasugrel, in vitro
cangrelor is associated with further platelet P2Y12 receptor inhibitory effects. (J Am Coll Cardiol Intv 2014;7:426–34) ª 2014 by the
American College of Cardiology FoundationPrasugrel is a potent oral adenosine diphosphate (ADP)
P2Y12 receptor inhibitor approved for clinical use in pati-
ents with acute coronary syndrome (ACS) undergoing
percutaneous coronary intervention (PCI) (1–3). Despite
the more rapid and potent levels of platelet inhibition ach-
ieved compared with clopidogrel, pharmacodynamic (PD)
studies have shown interindividual variability in prasugrel
effects (4–8). Importantly, prasugrel-treated patients with
high on-treatment platelet reactivity (HPR) are at increased
risk of ischemic events (5). Delayed antiplatelet effects
and high rates of HPR have been shown particularly in
the early hours after prasugrel administration in patients
with ST-segment elevation myocardial infarction (STEMI)
undergoing primary PCI (9,10). Similar PD ﬁndings also
occur with ticagrelor (9–11). In patients on maintenance
prasugrel therapy, prasugrel reloading is associated with
enhanced platelet inhibition and reduced rates of HPRSquibb, sanoﬁ-aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The
Medicines Company, AstraZeneca, Evolva, and Gilead; and has received an Esther
and King Biomedical Research Grant. All other authors have reported that they have
no relationships relevant to the contents of this paper to disclose.
Manuscript received September 25, 2013; revised manuscript received
October 26, 2013, accepted November 21, 2013.(7,12). However, several hours are required to
achieve maximal antiplatelet effects (7,12). Ultimately, the
use of orally-administered antiplatelet agents may be chal-
lenging in patients unable to swallow (e.g., patients who are
sedated, intubated, or in shock, or those with nausea or
vomiting). Overall, these observations support the need for
intravenous antiplatelet therapies able to yield more prompt
and potent platelet inhibitory effects, which are unlikely to
be achieved with oral medications (8).
Cangrelor, a nonthienopyridine adenosine triphosphate
analogue, is a potent intravenous direct-acting and reversible
P2Y12 receptor antagonist that has been shown to reduce
ischemic complications, including stent thrombosis, in P2Y12
inhibitor–naïve patients undergoing PCI (13,14). Previous
investigations have reported that in vitro exposure of
cangrelor on platelets from clopidogrel-treated patients is
associated with potent P2Y12 inhibitory effects (15–17).
Whether cangrelor can exert rapid and further platelet
inhibitory effects on platelets from patients treated with pra-
sugrel is unknown. The aim of this PD investigation was to
assess the in vitro effects of cangrelor on platelets frompatients
with coronary artery disease onmaintenance prasugrel therapy
treated with 2 reloading dose regimens.
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428Methods
Study population and research design. This was a pro-
spective, randomized PD study conducted in 60 patients on
maintenance dual antiplatelet therapy with aspirin and
prasugrel. All patients had a clinical indication to be on
prasugrel as they all underwent PCI with an ACS (1–3).
Patients were clinically stable at time of study entry. Patients
were screened at the outpatient clinic of the Division of
Cardiology of the University of Florida College
of Medicine–UF Health Jacksonville. All patients were
considered eligible for the study if they were between 18 and
74 years of age and were receiving treatment with aspirinFigure 1. Study Design
PCI ¼ percutaneous coronary intervention.
Abbreviations
and Acronyms
ACS = acute coronary
syndrome
ADP = adenosine
diphosphate
ANCOVA = analysis of
covariance
ANOVA = analysis of variance
HPR = high on-treatment
platelet reactivity
MFI = mean ﬂuorescence
intensity
PCI = percutaneous coronary
intervention
PD = pharmacodynamic
PGE1 = prostaglandin E1
PRI = platelet reactivity
index
STEMI = ST-segment
elevation myocardial
infarction
VASP = whole-blood
vasodilator-stimulated
phosphoprotein
VASP-P = whole-blood
vasodilator-stimulated
phosphorylation(81 mg/day) and prasugrel (10
mg/day) for at least 14 days as
part of their standard of care dual
antiplatelet treatment regimen.
Exclusion criteria for this study
included active bleeding, previ-
ous cerebrovascular event, body
weight <60 kg, 75 years of age or
older, clinical instability after the
index event, use of oral anti-
coagulation, platelet count <100
 106/ml, hemoglobin <10 g/dl,
creatinine >2 mg/dl; hepatic
enzymes >2.5 times the upper
limit of normal; and pregnant
and lactating females were also
excluded.
Using a computer-based rando-
mization system, patients were
randomized in a 1:1 fashion to
either a 30- or 60-mg reload of
prasugrel. Blood samples were
collected at 3 time points: at base-
line (while on maintenance prasu-
grel therapy), at 1 h and at 4 h after
prasugrel reload. Blood sampling
for PD analysis were collected
by the antecubital vein in sodiumcitrate (0.105M)-containing tubes using a 19-gauge needle.The
ﬁrst few milliliters of blood sampled were discarded to avoid
spontaneous platelet activation. Baseline blood samples were
collected 24 4 h after the last maintenance dose of prasugrel in
order to assess trough levels of platelet reactivity. PD assessments
were performed with and without in vitro cangrelor (500 nM
cangrelor) at each time point. Tubes were immediately incu-
bated at 37C in a water bath, and cangrelor was added to the
whole blood and incubated for 5 min (17). The concentration
of cangrelor used in vitro was chosen in line with previous
investigations (15–17). This concentration approximates that
of the mean steady-state plasma concentration of 484 nmol/l
at the infusion dose of 4 mg/kg/min, which corresponds to thedose used in large-scale phase III clinical trial investiga-
tions (13,14,18,19). A ﬂow diagram of the study design is
shown in Figure 1. The study complied with the Declaration
of Helsinki, and was approved by the Institutional Review
Board of the University of Florida College of Medicine-
Jacksonville, and all patients gave their informed written
consent.
Whole-blood vasodilator-stimulated phosphoprotein. The
whole-blood vasodilator-stimulated phosphoprotein (VASP)
assay was used to determine the platelet reactivity index
(PRI) according to standard protocols (12,16). VASP was
performed before and after in vitro incubation with 500 nM
cangrelor at each time point. In brief, whole-blood vasodi-
lator-stimulated phosphoprotein phosphorylation (VASP-P)
was measured by quantitative ﬂow cytometry using commer-
cially-available labeled monoclonal antibodies (Biocytex Inc.,
Marseille, France). The PRI was calculated after measuring
the mean ﬂuorescence intensity (MFI) of VASP-P levels after
challenge with prostaglandin E1 (PGE1) and PGE1þADP.
PGE1 increases VASP-P levels through stimulation of ade-
nylate cyclase. ADP binding to purinergic receptors leads to
inhibition of adenylate cyclase; thus, the addition of ADP to
PGE1-stimulated platelets reduces levels of PGE1-induced
VASP-P. The PRI was calculated as follows: [(MFI
PGE1)  (MFI PGE1þADP)/(MFI PGE1)]  100%. A
reduced PRI is indicative of greater inhibition of the P2Y12
signaling pathway (12,16). Absolute levels as well as absolute
changes or delta (deﬁned as the difference with and without
cangrelor) of PRI, were calculated.
Sample size calculation and study endpoints. The primary
endpoint of the study was the comparison of PRI before and
Table 1. Baseline Characteristics
Variable
Prasugrel
p Value
30 mg
(N ¼ 30)
60 mg
(N ¼ 30)
Age, yrs 54.9  9.4 56.3  8.7 0.563
Male 23 (76.7) 23 (76.7) >0.999
BMI, kg/m2 33.6  9 32.1  6.3 0.476
Race 0.326
Caucasian 24 (80) 27 (90)
African American 5 (16.7) 2 (6.7)
Hispanic 0 1 (3.3)
Asian 1 (3.3) 0
Hypertension 28 (93.3) 25 (83.3) 0.424
Dyslipidemia 28 (93.3) 27 (90) >0.999
Smoking 9 (30) 9 (30) >0.999
Diabetes mellitus 6 (20) 9 (30) 0.371
Previous MI 26 (86.7) 25 (83.3) >0.999
Previous CABG 0 5 (16.7) 0.052
Medications
Beta-blockers 27 (90) 26 (86.7) >0.999
ACEI/ARB 26 (86.7) 29 (96.7) 0.353
Statins 30 (100) 28 (93.3) 0.269
PPI 5 (16.7) 7 (23.3) 0.684
CCB 4 (13.3) 7 (23.3) 0.506
Nitrates 7 (23.3) 11 (36.7) 0.260
LVEF >50% 20 (66.7) 24 (80) 0.511
Creatinine clearance, ml/min 114.6  52 122.4  38 0.524
Hematocrit, % 42.1  3.2 40.8  4.3 0.233
Platelet count, 1,000/mm3 223.3  48.6 223.1  52.7 0.986
Values are mean  SD or n (%).
ACEI/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI ¼
body mass index; CABG ¼ coronary artery bypass graft surgery; CCB ¼ calcium channel
blockers; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PCI ¼ percuta-
neous coronary intervention; PPI ¼ proton pump inhibitor.
Figure 2. Subject Disposition
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429after in vitro incubation with cangrelor at baseline, while
patients were on maintenance prasugrel 10 mg/day.
Assuming an SD of 20% and a dropout rate of w10%, we
would be able to detect a difference of 10% in baseline PRI
values before and after in vitro incubation with cangrelor with
60 patients, with a 95% power and a 2-tailed alpha value of
0.05. A cutoff of 10% absolute change in PRI was chosen as
this has been associated with a 44% relative reduction of
thrombotic events in patients undergoing PCI (20). Other
endpoints included intergroup comparisons (prasugrel 30 mg
vs. 60 mg) of PRI in the presence and absence of cangrelor
during the overall study time course and at each time point;
intragroup comparisons (prasugrel 30 mg vs. prasugrel 30 mg
plus cangrelor; prasugrel 60 mg vs. prasugrel 60 mg plus
cangrelor) of PRI during the overall study time course and at
each time point; and intergroup comparisons of the absolute
changes (delta) in PRI levels (before and after in vitro in-
cubation with cangrelor) for each group during the overall
study time course and at each time point.
Statistical analysis. Conformity to the normal distribution
was evaluated for continuous variables with the Kolmo-
gorov-Smirnov test. For baseline characteristics, continuous
variables are expressed as mean  SD, and categorical var-
iables are expressed as frequencies and percentages. The chi-
square or Fisher exact test (if the expected value in any cell
was <5) was used to compare categorical variables between
the 2 groups. A repeated-measures analysis of variance
(ANOVA) model was used to evaluate intragroup compar-
isons and the overall difference between groups, using
Bonferroni approach to correct for multiple comparisons.
An analysis of covariance (ANCOVA) method with a
general linear model, using the baseline value of platelet
reactivity as a covariate, was used to evaluate all between-
group comparisons. A 2-tailed p value <0.05 was consideredto indicate a statistically signiﬁcant difference for all of the
analyses performed. Results are reported as least-square
mean  SE for the previously detailed analyses. Statistical
analysis was performed using SPSS version 21.0 (SPSS Inc.,
Chicago, Illinois).
Results
Patient population. Between July 2011 and March 2013, a
total of 79 patients meeting study inclusion criteria were
identiﬁed. Of these, 19 declined to participate; therefore, a
total of 60 patients on maintenance prasugrel 10 mg/day
therapy were randomly assigned to a reload with either 30
mg (n ¼ 30) or 60 mg (n ¼ 30) of prasugrel. One patient in
the 30-mg reload group had all samples hemolyzed and was
thus not available for analysis. Patient disposition is sum-
marized in Figure 2. Baseline characteristics of the study
population are summarized in Table 1. There were no dif-
ferences in baseline characteristics between groups (Table 1).
Figure 3. Comparison of Platelet Reactivity Values in a 30- and 60-mg Prasugrel Reloading Dose in the Absence of Cangrelor
Platelet reactivity index expressed as percentages measured by whole-blood vasodilator-stimulated phosphoprotein in the absence of cangrelor before and after
reload with 30 or 60 mg prasugrel. Data are presented as least square means. Error bars indicate SE. The baseline histogram represents aggregate data of the 2 groups.
Analysis of variance (ANOVA) p value refers to the overall difference in platelet reactivity index between the 30- and 60-mg reloading doses. Analysis of covariance
(ANCOVA) p values are provided for intergroup comparisons at each time point. Intragroup comparisons are speciﬁed at the bottom of the ﬁgure. ANOVA p value
indicates the overall intragroup difference across time points.
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values were similar between groups at baseline (p ¼ 0.378).
Moreover, in the intergroup analysis comparing a 30- and
60-mg prasugrel reload, PRI values were not signiﬁcantly
reduced during the overall time course between the 2
reloading dose regimens (ANOVA, p ¼ 0.935). PRI at 4 h
after a 60-mg reload was markedly reduced compared with
a 30-mg reload (ANCOVA, p ¼ 0.001), but not at 1 h
(ANCOVA, p ¼ 0.481) (Fig. 3). In the intragroup analysis,
prasugrel reloading signiﬁcantly reduced PRI levels after
1 and 4 h with both 30- and 60-mg reloading doses
(p < 0.001 for both doses by ANOVA). There was greater
platelet inhibition between 1 and 4 h in the 60-mg group,
but not in the 30-mg group (Fig. 3).
In vitro PD effects of cangrelor after a 30-mg prasugrel
reload. In patients receiving a 30-mg reload of prasugrel, in
vitro cangrelor was associated with enhanced additive P2Y12
receptor inhibition. In particular, PRI values were signiﬁ-
cantly reduced during the overall time course (ANOVA,
p ¼ 0.001) and at each time point compared with PRI values
without cangrelor (baseline, p < 0.001; 1 h, p ¼ 0.013; 4 h,
p ¼ 0.001) (Fig. 4A). Moreover, intragroup comparisons
showed cangrelor to be associated with further inhibition in
addition to that with prasugrel across time points (ANOVA,
p < 0.001), with a signiﬁcant difference in PRI levelsbetween baseline and 1 h (p ¼ 0.002) and between baseline
and 4 h (p < 0.001); there was a nonsigniﬁcant reduction in
PRI between 1 and 4 h (p ¼ 0.401) (Fig. 4A).
In vitro PD effects of cangrelor after a 60-mg prasugrel
reload. In patients receiving a 60-mg reload of prasugrel, in
vitro incubation with cangrelor was associated with a sig-
niﬁcant difference in PRI values during the overall study
time course (ANOVA, p < 0.001). Cangrelor markedly
reduced PRI levels at baseline (p < 0.001) and at 1 h
(p ¼ 0.002) after a 60-mg prasugrel reload. However, 4 h
after a 60-mg prasugrel reload, cangrelor led to a nonsig-
niﬁcant reduction in PRI (p ¼ 0.325) (Fig. 4B). Intragroup
comparisons showed cangrelor to be associated with
enhanced platelet inhibitory effects across time points
(ANOVA, p ¼ 0.001) and a further signiﬁcant reduction in
PRI between baseline and 4 h (p ¼ 0.005) as well as between
1 and 4 h (p ¼ 0.016); there was a nonsigniﬁcant reduction
in PRI between baseline and 1 h (p ¼ 0.124) (Fig. 4B).
In vitro PD effects of cangrelor in patients reloaded with
prasugrel 30 mg versus 60 mg. After in vitro incubation
with cangrelor, PRI values were similar between the 30- and
60-mg prasugrel reload groups at baseline. In the intergroup
analysis, absolute PRI levels (ANOVA, p ¼ 0.373)
(Fig. 5A) and absolute changes (delta) in PRI (ANOVA,
p ¼ 0.290) (Fig. 5B) were not signiﬁcantly reduced between
Figure 4. Platelet Reactivity Values Across Time Points After a
30- and 60-mg Prasugrel Reloading Dose in the Presence and
Absence of Cangrelor
(A) Comparison of platelet reactivity index (PRI) expressed as percentages (%)
measured by whole-blood vasodilator-stimulated phosphoprotein across time
points in the 30-mg prasugrel reload group in the presence and absence of
cangrelor. (B) Comparison of PRI expressed as percentages measured by
whole-blood vasodilator-stimulated phosphoprotein across time points in the
60-mg prasugrel group in the presence and absence of cangrelor. Data are
presented as least square means. Error bars indicate SE. p values are provided
for the intergroup comparisons. Analysis of variance (ANOVA) p value refers to
the overall difference in PRI with and without cangrelor across time points in
A and B. Intragroup comparisons are speciﬁed at the bottom of the ﬁgure.
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431the 2 groups during the overall time course. Similarly, there
were no signiﬁcant differences at any individual time point
(Figs. 5A and 5B).
Discussion
The platelet P2Y12 receptor is key in mediating platelet
activation and aggregation processes (8,21–24). The present
PD investigation was performed to elucidate the in vitro
effects of cangrelor on P2Y12-mediated signaling in patients
treated with prasugrel maintenance therapy after reloading
with either a 30- or 60-mg dose. Our PD investigationshowed the following: 1) in vitro cangrelor is associated with
enhanced platelet inhibition when added to platelets from
patients on prasugrel maintenance therapy as well as when
exposed to a reloading dose; 2) platelet inhibitory effects of
in vitro cangrelor are immediate and faster than prasugrel
reloading alone; and 3) levels of platelet reactivity to com-
parable those achieved with in vitro cangrelor were observed
only 4 h after a 60-mg prasugrel reloading dose.
Adjunctive therapy with a platelet P2Y12 receptor inhib-
itor is key for reduction of thrombotic risk in patients with
ACS and undergoing PCI (1–3). Currently, only oral P2Y12
receptor inhibitors are available for clinical use (8). Clopi-
dogrel is the most widely used P2Y12 receptor inhibitor
and is characterized by nonuniform PD effects, a phenom-
enon associated with an increased risk of adverse outcomes
(23–26). Prasugrel and ticagrelor are newer-generation
P2Y12 receptor inhibitors that are both characterized by a
more rapid onset of action, greater potency, and more uni-
form PD effects compared with clopidogrel (8,27,28). These
PD properties may explain the enhanced ischemic beneﬁt,
albeit at the expense of increased bleeding, with these agents
compared with clopidogrel in ACS patients (27,28). How-
ever, despite these important advancements in oral P2Y12
receptor–inhibiting strategies, prasugrel and ticagrelor have
also recently both been found to have variability in PD
response with the potential for worse clinical outcomes
(4,5,7,9–11). Moreover, prasugrel and ticagrelor have
consistently been shown to have a delayed onset of action in
patients with STEMI undergoing primary PCI, requiring
at least 2 h to exert their full antiplatelet effects and thus
exposing these high-risk patients to an increased risk of
thrombotic complications (9,10). Increasing the loading-
dose regimen of these oral agents has been advocated,
although the limited data thus far have not shown mean-
ingful changes in antiplatelet effects (29,30). Inability to
achieve adequate platelet inhibition with oral P2Y12
receptor inhibitors is also a concern in other common clinical
settings, such as patients unable to swallow oral medications
(i.e., patients who are sedated, intubated, in shock, or those
with nausea or vomiting). Furthermore, patients in certain
high-risk settings such as STEMI and therapeutic hypo-
thermia may also have impaired intestinal absorption and
hepatic metabolism that can limit the pharmacological efﬁ-
cacy of oral P2Y12 receptor inhibitors and increase the risk of
stent thrombosis (31–33). These ﬁndings underscore the
need for an intravenous agent with prompt, potent, and
predictable antiplatelet properties.
Currently, glycoprotein IIb/IIIa inhibitors are the only
antiplatelet agents clinically available for intravenous use and
indeed have been shown to be advantageous in patients
requiring immediate and potent platelet inhibition (34).
Recently, Valgimigli et al. (35) showed that, in STEMI
patients undergoing primary PCI, 60 mg prasugrel was
associated with suboptimal platelet inhibition for at least 2 h
Figure 5. Comparison of Platelet Reactivity Values Between 30- and
60-mg Prasugrel Reloading Doses in the Presence of Cangrelor
(A) Comparison of platelet reactivity index (PRI) expressed as percentages
measured by whole-blood vasodilator-stimulated phosphoprotein across time
points between 30- and 60-mg prasugrel reloading dose regimens in the
presence of cangrelor. The ANOVA p value refers to the overall difference in
PRI between the 2 reloading doses. Analysis of covariance (ANCOVA) p values
are provided for intergroup comparisons at each time point. (B) Absolute
change or delta (D) between PRI values in the absence and presence of
cangrelor in each arm (30- and 60-mg prasugrel reload) is provided. ANOVA p
value refers to the overall difference between groups across time points. The
baseline histogram represents aggregate data of the 2 groups. Data are
presented as least square means. Error bars indicate SE. p values are provided
for intergroup comparisons.
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only obviated the need for an infusion but also led to nearly
complete elimination of residual variability of platelet inhi-
bition. However, glycoprotein IIb/IIIa inhibitor use is in
decline, given the high risk of bleeding complications and
the introduction of alternative antithrombotic treatment
regimens that have been shown to have a more favorable
safety proﬁle, without any trade-off in clinical efﬁcacy (34).
Nevertheless, periprocedural thrombotic complications still
remain a concern, highlighting the need for effective
platelet-inhibiting strategies (8).
Cangrelor is a potent intravenous, direct-acting (no
metabolism required) P2Y12 receptor inhibitor with an im-
mediate onset of action (36). Moreover, cangrelor has an
ultra-short half-life (3 to 6 min), leading to a very rapid
offset of action with return to baseline platelet function
within 30 to 60 min (36). These PD properties mayrepresent a potential treatment option in patients undergo-
ing surgery and who cannot discontinue P2Y12 inhibiting
therapy (37,38). Further, cangrelor may represent an
attractive treatment option in PCI patients in whom im-
mediate and potent P2Y12 receptor blockade is required.
Although, 2 phase III clinical trials failed to meet the pri-
mary efﬁcacy endpoint, likely attributed to the deﬁnition of
the study endpoints, the primary efﬁcacy endpoint was met
in the recently reported CHAMPION PHOENIX (Effect
of Platelet Inhibition with Cangrelor during PCI on
Ischemic Events) trial (13,18,19). In this trial, conducted in
11,145 clopidogrel-naïve patients undergoing PCI, cangre-
lor signiﬁcantly reduced the rate of ischemic events at 48 h,
including stent thrombosis, with no signiﬁcant increase in
severe bleeding, irrespective of clinical presentation (stable
angina, unstable angina/non-STEMI, STEMI) (13).
Concerns have emerged regarding the potential for drug
interactions with oral P2Y12 receptor inhibitors when using
cangrelor. In an ex vivo PD investigation conducted in
healthy volunteers, it was shown that if patients were
administered clopidogrel during a cangrelor infusion, clo-
pidogrel would be ineffective, given that its active metabolite
would not bind with the P2Y12 receptor while occupied by
cangrelor (39). Clopidogrel PD was not affected when
administered after cangrelor infusion, given its very rapid
offset of action. Similarly, in vitro pre-incubation of blood
with cangrelor before addition of active metabolites of clo-
pidogrel or prasugrel reduced their ability to inhibit platelet
aggregation (40). In contrast, cangrelor added after pre-in-
cubation with the active metabolites of clopidogrel or pra-
sugrel led to sustained platelet inhibition. Therefore, phase
III clinical investigations reinforced that clopidogrel (the
only oral P2Y12 inhibitor used in these trials) should be
administered only at the end of cangrelor infusion to be
effective (13,18,19). The optimal transition strategy from
cangrelor to prasugrel or ticagrelor is currently under
investigation (Clinical Trial numbers NCT01852019 and
NCT01766466).
There is limited experience with understanding the ef-
fects of cangrelor when added to platelets already exposed to
an oral P2Y12 receptor inhibitor. Previous investigations
have shown that the addition of therapeutic concentrations
of cangrelor in vitro before and after clopidogrel adminis-
tration enhances P2Y12 inhibitory effects (15–17). The
novelty of our investigation is that it expands our under-
standing of the in vitro PD effects of cangrelor by assessing
patients on prasugrel therapy. In vitro addition of cangrelor
provides a signiﬁcant reduction in PRI before and after
prasugrel reloading in patients already on maintenance
prasugrel therapy, indicating that not all P2Y12 receptors
have been occupied by binding with the active metabolite
of orally-administered prasugrel. These ﬁndings suggest
that even though prasugrel is a potent P2Y12 receptor in-
hibitor, it is not able to rapidly inhibit platelet reactivity to
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433the degree observed with cangrelor. However, it should also
be noted that after in vitro cangrelor, PRI levels at baseline,
while patients were on maintenance prasugrel therapy, were
not as low as those observed 1 and 4 h after prasugrel reload.
This ﬁnding is indicative of an additive effect over time with
a prasugrel reload. It may be argued, however, that previous
in vitro studies with cangrelor conducted in stable cardio-
vascular patients treated with clopidogrel showed lower levels
of platelet reactivity (16). Nevertheless, our study population
comprised patients who had experienced an ACS and thus
were more likely to have a hyper-reactive platelet phenotype
and who were exposed to reloading doses of a more potent
antiplatelet agent (i.e., prasugrel), which can explain the
changes in PRI over the course of the study. Indeed, higher
in vitro concentrations of cangrelor (10 mM), as used by Aleil
et al. (16), could have led to more potent inhibition of PRI,
even at baseline. However, such a high concentration of
cangrelor would not be reﬂective of that which will be
potentially used in clinical practice and likely increase the risk
of bleeding complications (23).
Although a 60-mg reload is able to achieve more potent
antiplatelet effects than a 30-mg reload, conﬁrming a pre-
vious investigation (12), levels of platelet reactivity compa-
rable to those achieved with cangrelor are achieved only 4 h
after a 60-mg prasugrel reload in patients already on
maintenance therapy. Indeed, although a reloading dose
regimen of prasugrel led to signiﬁcant changes in platelet
reactivity as soon as 1 h in this investigation, clinical studies
have shown that in higher-risk settings, such as STEMI,
this may require longer time frames (9,10,35). Immediate
platelet inhibition is desired at the time of coronary inter-
vention. Our study showed that cangrelor was associated
with anw15% further absolute reduction in PRI in patients
on maintenance prasugrel therapy, which was consistent over
time, irrespective of the prasugrel loading-dose regimen. Of
note, for each 10% absolute reduction in PRI, a 44% relative
reduction in thrombotic events in patients undergoing PCI
has been shown (20). Whether cangrelor can exert similar
effects in ticagrelor-treated patients remains to be
established.
Study limitations. The main limitation of the present
investigation is derived from its very design, since in vitro
conditions make the results of this study exploratory, and
ex vivo PD studies are warranted to conﬁrm these ﬁndings.
Moreover, although this study was conducted in patients
who experienced an ACS, platelet reactivity was assessed
remotely from their ACS presentation. Thus, the PD
ﬁndings with a combination of prasugrel and cangrelor
warrant conﬁrmation in the setting of ACS patients un-
dergoing PCI. Indeed, the forthcoming HORIZONS AMI
II study (Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction) trial, in which
cangrelor will be used in a large cohort of patients withSTEMI undergoing primary PCI treated with a novel
generation P2Y12 inhibitor, will be pivotal for a better un-
derstanding of these effects. Further, platelet reactivity was
assessed only with VASP-PRI. Indeed, adding additional
PD assays would have corroborated our study ﬁndings,
although VASP-PRI is most speciﬁc to assess P2Y12 re-
ceptor–mediated signaling (16,24). Further, although pre-
vious investigations have identiﬁed variability in response to
prasugrel (4–8), the sample size of our study did not allow us
to explore contributors to this phenomenon.Conclusions
In patients on maintenance prasugrel therapy exposed to a
reloading dose regimen (30 or 60 mg) of prasugrel, in vitro
cangrelor is associated with further platelet P2Y12 receptor
inhibitory effects as assessed by VASP-PRI. Levels of
platelet reactivity comparable to those achieved with can-
grelor were observed 4 h after a 60-mg prasugrel reload,
making cangrelor an attractive strategy if more prompt an-
tiplatelet effects are required. Ex vivo studies in patients
undergoing PCI are warranted to conﬁrm these in vitro
ﬁndings.
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